# Phase 3 Study to Assess the Efficacy and Safety of Batoclimab as Induction and Maintenance Therapy in Adult Participants With Generalized Myasthenia Gravis

> **NCT05403541** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Immunovant Sciences GmbH** · enrollment: 240 (estimated)

## Conditions studied

- Generalized Myasthenia Gravis

## Interventions

- **DRUG:** Batoclimab 680 mg SC weekly
- **DRUG:** Batoclimab 340 mg SC weekly
- **DRUG:** Matching Placebo SC
- **DRUG:** Batoclimab 340 mg SC bi-weekly

## Key facts

- **NCT ID:** NCT05403541
- **Lead sponsor:** Immunovant Sciences GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-06-27
- **Primary completion:** 2025-01-10
- **Final completion:** 2027-02
- **Target enrollment:** 240 (ESTIMATED)
- **Last updated:** 2026-03-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05403541

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05403541, "Phase 3 Study to Assess the Efficacy and Safety of Batoclimab as Induction and Maintenance Therapy in Adult Participants With Generalized Myasthenia Gravis". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT05403541. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*